|4Feb 28, 6:19 PM ET

Albertson Tina M. 4

4 · Lyell Immunopharma, Inc. · Filed Feb 28, 2023

Insider Transaction Report

Form 4
Period: 2023-02-24
Albertson Tina M.
Chief Medical Officer
Transactions
  • Award

    Option (right to buy)

    2023-02-24+700,000700,000 total
    Exercise: $2.13Exp: 2033-02-23Common Stock (700,000 underlying)
Holdings
  • Common Stock

    4,049
Footnotes (2)
  • [F1]Includes 2,495 shares acquired on May 18, 2022 and 1,554 shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
  • [F2]12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION